The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Update of phase 1b/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced/metastatic MSS CRC.
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Coherus Biosciences; Eisai; Exelixis; Genentech; Jazz Pharmaceuticals; Merck; Sumitomo Pharma Oncology; TransThera Biosciences; TriSalus Life Sciences
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst)
 
Sun Young Kim
Honoraria - Boryung; LG Chem; Merck
Consulting or Advisory Role - Guardant Health; Ono Pharmaceutical; Roche
Research Funding - Roche/Genentech (Inst)
Expert Testimony - Guardant Health
 
Hee Kyung Kim
No Relationships to Disclose
 
Sunil Sharma
Stock and Other Ownership Interests - Barricade Therapeutics; Beta Cat Pharmaceuticals; Black Canyon Bio; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma
Consulting or Advisory Role - Agastiya Biotech; Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics; Incyte; Mirati Therapeutics; Novelty Nobility; Processa Pharmaceuticals, Inc; Rappta Therapeutics; Stemline Therapeutics
Research Funding - AADi; Adagene (Inst); Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Nimbus Therapeutics (Inst); Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
 
Sang Joon Shin
No Relationships to Disclose
 
Jeeyun Lee
Consulting or Advisory Role - AstraZeneca; Guardant Health AMEA; Mirati Therapeutics; Oncologie; Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme
 
Sae-Won Han
Honoraria - IMBdx
Consulting or Advisory Role - AstraZeneca
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); BeyondBio (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst); Turnstone Bio (Inst)
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Abbvie; Adagene; Bayer; BMS; Delcath Systems; Eisai; Entos; Janssen Research & Development; Merck; Microbial Machines; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Tempus; Totus Medicines
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Luke Chung
Employment - Adagene
Stock and Other Ownership Interests - Adagene
 
Yan Li
Employment - Adagene
Leadership - Adagene
Stock and Other Ownership Interests - Adagene
Patents, Royalties, Other Intellectual Property - Adagene
 
Ping Xiao
Employment - Adagene
 
Songmao Zheng
Employment - Adagene
Leadership - Adagene
Stock and Other Ownership Interests - Adagene
 
Kristine She
Employment - Adagene
Stock and Other Ownership Interests - Adagene
 
Dana Hu-Lowe
Employment - Adagene
Stock and Other Ownership Interests - Adagene
 
Jiangchun Xu
Employment - Adagene
Stock and Other Ownership Interests - Adagene
 
Stanley Frankel
Employment - Cytovia Therapeutics
Leadership - Myeloid Therapeutics; Precision Biosciences
Stock and Other Ownership Interests - Adagene; Precision Biosciences; Sutro Biopharma
Honoraria - Chimeric Therapeutics; OPKO Health
Consulting or Advisory Role - Adagene; AstraZeneca; Autolus Therapeutics; Cargo Therapeutics; Deka Bioscience; Harpoon therapeutics; Immunai; Myeloid Therapeutics; Precision Biosciences; Sutro Biopharma
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Peter Luo
Employment - Adagene
Leadership - Adagene
Stock and Other Ownership Interests - Adagene
Patents, Royalties, Other Intellectual Property - patents pending
 
Jiping Zha
Employment - Adagene
Leadership - Adagene
Stock and Other Ownership Interests - Adagene
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Kura Oncology; Mitsubishi Tanabe Pharma; Nurix; shivanka Research
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)